1999
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment
Elsworth J, Taylor J, Sladek J, Collier T, Redmond D, Roth R. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 1999, 95: 399-408. PMID: 10658619, DOI: 10.1016/s0306-4522(99)00437-6.Peer-Reviewed Original ResearchConceptsHomovanillic acid/dopamine ratioMPTP treatmentStriatal dopamine levelsDopamine levelsDopamine lossDopamine depletionDopamine ratioStriatal subregionsNucleus accumbensCaudate nucleusDopamine concentrationsOne-yearSeverity categoriesDopamine neuron integrityVentromedial caudate nucleusStriatal dopamine lossHomovanillic acid concentrationsStriatal dopaminergic functionMarked increaseNormal motor performancePaucity of dataMetabolic activityNon-human primatesParkinsonian disabilityTetrahydropyridine (MPTP) model
1990
MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys
Elsworth J, Deutch A, Redmond D, Sladek J, Roth R. MPTP-induced parkinsonism: relative changes in dopamine concentration in subregions of substantia nigra, ventral tegmental area and retrorubral field of symptomatic and asymptomatic vervet monkeys. Brain Research 1990, 513: 320-324. PMID: 2350702, DOI: 10.1016/0006-8993(90)90474-p.Peer-Reviewed Original ResearchConceptsVentral tegmental areaSubstantia nigraTegmental areaRetrorubral fieldParkinson's diseasePostencephalitic Parkinson's diseaseHomovanillic acid concentrationsMesostriatal dopaminergic systemIdiopathic Parkinson's diseaseAsymptomatic monkeysSymptomatic monkeysDA neuronsHVA concentrationsMPTP toxicityTreatment regimensDopaminergic systemDopamine concentrationsDA regionsDiseaseNigraDopamineParkinsonismMonkeysVervet monkeysRegimens
1989
Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions
Elsworth J, Deutch A, Redmond D, Taylor J, Sladek J, Roth R. Symptomatic and asymptomatic 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridinetreated primates: Biochemical changes in striatal regions. Neuroscience 1989, 33: 323-331. PMID: 2622529, DOI: 10.1016/0306-4522(89)90212-1.Peer-Reviewed Original ResearchConceptsHomovanillic acid concentrationsParkinson's diseaseStriatal regionsHomovanillic acid/dopamine ratioGross motor abnormalitiesDepletion of dopamineHomovanillic acid levelsLoss of dopamineIdiopathic Parkinson's diseaseCaudate nucleus dopamineAsymptomatic monkeysTetrahydropyridine (MPTP) treatmentAsymptomatic groupSymptomatic groupDopamine lossTetrahydropyridine (MPTP) toxicityMotor abnormalitiesDopamine ratioCaudate nucleusSignificant negative correlationVentromedial regionStriatum
1987
Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates
Elsworth J, Leahy D, Roth R, Redmond D. Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. Journal Of Neural Transmission 1987, 68: 51-62. PMID: 3806086, DOI: 10.1007/bf01244639.Peer-Reviewed Original ResearchConceptsHomovanillic acid concentrationsDorsal frontal cortexFrontal cortexHVA concentrationsCentral dopamine functionCSF HVA concentrationsCentral dopamine metabolismBasal ganglia areaOrbital frontal cortexSignificant correlationPossible treatment effectsPlasma HVAGanglia areaDopamine metabolismCaudate nucleusCortical areasDopamine functionBrain areasCisternal CSFBrain regionsHVA measurementsCortex contributesCSFCortexOnly significant relationship